Information for Researchers

Availability of Wave 1 Biomarker Data Restricted Use Files and Launch of Biospecimen Access Program

The Population Assessment of Tobacco and Health (PATH) Study is a household-based, nationally representative, longitudinal cohort study of approximately 46,000 youth and adults in the United States. The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) announce the availability of restricted-use biomarker data files (Biomarker RUF) from the first wave of the PATH Study, in addition to the launch of the Study’s new Biospecimen Access Program that provides the research community with access to urine, serum, and plasma collected from adult study participants during Wave 1.

With over 21,000 adult study participants providing a urine specimen and over 14,000 providing a blood specimen (most of whom also provided a urine specimen) in Wave 1, the newly released Biomarker RUF contain the results of laboratory analyses for a subset of the specimens. The files include measurements of arsenic, creatinine, metals, polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine metabolites, and volatile organic compounds in urine; and measurements of cotinine and hydroxycotinine in serum. Qualified researchers are encouraged to visit not government site to apply for access to the Biomarker RUF through the National Addiction & HIV Data Archive Program (NAHDAP) at the Inter-university Consortium for Political and Social Research (ICPSR).

The launch of the PATH Study’s Biospecimen Access Program, which now provides the research community with access to urine, serum, and plasma collected from adult PATH Study participants during Wave 1, has a separate web page that can be accessed on the NAHDAP website at not government site. This page provides information on the BAP’s policies, available biospecimens, and application procedures. Investigators proposing meritorious and feasible studies consistent with PATH Study objectives and/or research priorities for tobacco regulatory science will be given highest priority for access to these biospecimens, but proposals addressing other objectives that advance the knowledge of tobacco use and/or tobacco-related health outcomes will also be considered.

For more information on the PATH Study including access to the restricted- and public-use questionnaire data files for Waves 1 and 2, please visit: not government site.

Please share this information with others who may be interested.